Stock Analysis, Dividends, Split History

CRVW / Careview Communications, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)23.69
Enterprise Value ($M)23.46
Book Value ($M)-71.27
Book Value / Share-0.51
Price / Book-0.33
NCAV ($M)-79.09
NCAV / Share-0.57
Price / NCAV-0.30
Share Statistics
Common Stock Shares Outstanding 139,380,748
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 139,380,748
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.69
Return on Assets (ROA)-0.94
Return on Equity (ROE)0.47
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio0.22
Income Statement (mra) ($M)
Sales Revenue Net6,263,810.00
Operating Income-6.62
Net Income-20.07
Earnings Per Share Basic And Diluted-0.14
Cash Flow Statement (mra) ($M)
Cash From Operations-6.26
Cash from Investing-1.26
Cash from Financing-1.26
Identifiers and Descriptors
Central Index Key (CIK)1377149

Split History

Stock splits are used by Careview Communications, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

PDL Biopharma: Sum-Of-The-Parts Analysis Suggests Downside Protection, And Optionality On Private Equity Investments

2018-07-27 seekingalpha
PDLI looks cheap based on its net cash, fair value of royalty contract and loan portfolios. (2-1)

PDL BioPharma's (PDLI) CEO John McLaughlin on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good afternoon and welcome to the PDL BioPharma's earnings conference call for the first quarter 2018. Today's call is being recorded. For opening remarks and introductions, I would now like to turn the call over to Pete Garcia, Chief Financial Officer of PDL. (20-0)

CUSIP: 141743104